Shandong Weigao Group Medical Polymer Company Limited (“Weigao Group”) disclosed that it repurchased 187,600 H shares on 05 October 2026 through on-exchange transactions, paying between HKD 3.19 and HKD 3.20 per share. The volume-weighted average price was HKD 3.19, bringing total consideration to HKD 0.60 million.

Following the transaction, Weigao Group’s issued share capital (excluding treasury shares) fell to 4.46 billion shares, down 0.0042%. Treasury shares increased to 66.77 million, while the overall issued share count remained unchanged at 4.52 billion.

The buy-back forms part of the company’s share repurchase mandate approved on 29 May 2026, which authorises the repurchase of up to 446.46 million shares. To date, 9.44 million shares—equivalent to 2.11% of the issued share base on the mandate date—have been repurchased under this authorisation.

A 30-day moratorium on new share issues or further sales of treasury shares is in effect until 05 November 2026, in line with Hong Kong Stock Exchange regulations.